(
A) Schematic of the differentiation protocol used to generate hiPSC-derived dopamine neurons, including a patterning phase to generate neural progenitor cells followed by differentiation into mature neurons. Green arrows represent points of replating when cells are supplemented with ROCK inhibitor (Ri) to increase survival. BDNF, brain-derived neurotrophic factor; FGF8a, fibroblast growth factor 8a; GDNF, glial cell line-derived neurotrophic factor; Puro, puromorphamine; SHH, sonic hedgehog; TGF-β3, transforming growth factor beta 3 (see
Kriks et al., 2011;
Beevers et al., 2017;
Lang et al., 2019 for full details). Neurons are mature and harvested between 35 and 68 days for analysis. Immunocytochemical fluorescent images of mature neurons at day 50 stained for neuronal marker microtubule-associated protein (MAP2), the dopaminergic marker tyrosine hydroxylase (TH), and DAPI. Scale bar: 20 µm. (
B) DNAJC5 is palmitoylated in iPSC-derived dopamine neurons. Immunoblot analysis of DNAJC5 palmitoylation in hiPSC-derived dopamine neurons treated with DMSO, 7.5 μM Quercetin or 10 μM 2-BA on day 65 and harvested on day 68. TH was used as a marker of dopaminergic identity. (
C) Partial depalmitoylation of DNAJC5 by 2-BA in iPSC-derived dopamine neurons does not reduce α-syn secretion. hiPSC-derived dopamine neurons carrying the
GBA-N370S mutation were treated with palmitoylation inhibitor 2-BA (5 μM or 10 μM) at day 35. Culture media samples were harvested after 3 days treatment at day 38 and α-syn levels in the media were analyzed by electro-chemiluminescent immunoassay. Data points represent individual cell lines derived from different donors and are normalized to total protein in the corresponding cell lysates. One-way ANOVA shows no effect of 2-BA on α-syn secretion.